PATIENT AND PHYSICIAN SATISFACTION OF TREATMENT WITH ECULIZUMAB OR RAVULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM A REAL-WORLD DISEASE-SPECIFIC PROGRAMME

被引：0
|
作者：
Fureder, W. [1 ]
Mellor, J. [2 ]
Earl, L. [2 ]
Wang, A. [3 ]
Patel, Y. [1 ,3 ]
Myren, K. J. [1 ,3 ]
Nagalla, S. [4 ]
机构：
[1] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med I, Vienna, Austria
[2] Adelphi Real World, Bollington, England
[3] Alexion, Boston, MA USA
[4] Miami Canc Inst, Benign Hematol, Miami, FL USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR187
引用
收藏
页码：S347 / S347
页数：1
相关论文
共 50 条
  • [31] Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab
    Kulasekararaj, Austin G.
    Hill, Anita
    Rottinghaus, Scott T.
    Langemeijer, Saskia
    Wells, Richard A.
    Gonzalez-Fernandez, F. Ataulfo
    Gaya, Anna
    Lee, Jong-Wook
    Gutierrez, Emilio Ojeda
    Piatek, Caroline I.
    Szer, Jeffrey
    Risitano, Antonio M.
    Nakao, Shinji
    Bachman, Eric
    Shafner, Lori
    Damokosh, Andrew I.
    Ortiz, Stephan
    Roeth, Alexander
    De latour, Regis Peffault
    [J]. BLOOD, 2018, 132
  • [32] Improvements in Hemoglobin and Cognitive Function from Opera: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria
    Fishman, Jesse
    Min, Jinny
    Arnett, Lily
    Shenoy, Apeksha
    [J]. BLOOD, 2023, 142
  • [33] Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
    Ishiyama, Ken
    Nakao, Shinji
    Usuki, Kensuke
    Yonemura, Yuji
    Ikezoe, Takayuki
    Uchiyama, Michihiro
    Mori, Yasuo
    Fukuda, Tetsuya
    Okada, Masaya
    Fujiwara, Shin-ichiro
    Noji, Hideyoshi
    Rottinghaus, Scott
    Aguzzi, Rasha
    Yokosawa, Jun
    Nishimura, Jun-Ichi
    Kanakura, Yuzuru
    Okamoto, Shinichiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (04) : 466 - 476
  • [34] Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients
    Ken Ishiyama
    Shinji Nakao
    Kensuke Usuki
    Yuji Yonemura
    Takayuki Ikezoe
    Michihiro Uchiyama
    Yasuo Mori
    Tetsuya Fukuda
    Masaya Okada
    Shin-ichiro Fujiwara
    Hideyoshi Noji
    Scott Rottinghaus
    Rasha Aguzzi
    Jun Yokosawa
    Jun-Ichi Nishimura
    Yuzuru Kanakura
    Shinichiro Okamoto
    [J]. International Journal of Hematology, 2020, 112 : 466 - 476
  • [35] Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors receiving Ravulizumab or Eculizumab: results from a phase 3 non-inferiority study
    Roeth, A.
    Risitano, A.
    Jang, J. H.
    Lee, G. -W.
    Wanachiwanawin, W.
    Schrezenmeier, H.
    Yonemura, Y.
    Munir, T.
    Pavani, R.
    Aguzzi, R.
    Shafner, L.
    Kulagin, A.
    de Fontbrune, Sicre F.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 97 - 97
  • [36] EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
    Hoechsmann, B.
    de Fontbrune, F. Sicre
    Lee, J. W.
    Kulagin, A.
    Hillmen, P.
    Wilson, A.
    Marantz, J.
    Schrezenmeier, H.
    [J]. HAEMATOLOGICA, 2017, 102 : 188 - 189
  • [37] Trial in Progress: A Real-World Cohort Study Reporting Patient Profiles, Clinical Outcomes, and Unmet Medical Need of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in the Essen Center in Germany
    Versmold, Katharina
    Raiser, Carina
    Faghmous, Imi
    Katz, Pablo
    Shang, Aijing
    Xu, Tao
    Roth, Alexander
    [J]. BLOOD, 2020, 136
  • [38] EARLY HEMOGLOBIN AND QUALITY-OF-LIFE TRENDS FROM OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Fishman, J.
    Min, J.
    Arnett, L.
    Shenoy, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S20 - S20
  • [39] Real-World Patient Characteristics, Treatment Patterns and Outcomes for Patients with Atypical Hemolytic Uremic Syndrome Who Have Switched from Eculizumab to Ravulizumab in the USA
    Wang, Yan
    Al-Dakkak, Imad
    Garlo, Katherine
    Ong, Moh-Lim
    Tomazos, Ioannis
    Mahajerin, Arash
    [J]. BLOOD, 2021, 138
  • [40] Use and effect of eculizumab (ecu) in paroxysmal nocturnal hemoglobinuria (PNH) patients with or without high disease activity: Results from the International PNH Registry
    Hoechsmann, B.
    de Fontbrune, F. S.
    Lee, J-W
    Kulagin, A.
    Hillmen, P.
    Wilson, A.
    Marantz, J.
    Schrezenmeier, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 127 - 127
12345